These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32553612)

  • 1. Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma.
    Rubio-Rivas M; Moreira C; Marcoval J
    Autoimmun Rev; 2020 Aug; 19(8):102587. PubMed ID: 32553612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
    Luke JJ
    Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
    Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
    Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature.
    Anastasopoulou A; Diamantopoulos PT; Skalioti C; Liapis G; Psychogiou E; Ziogas DC; Gogas H
    Ther Adv Med Oncol; 2021; 13():17588359211047349. PubMed ID: 34691245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considering adjuvant therapy for stage II melanoma.
    Poklepovic AS; Luke JJ
    Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy.
    Gouveris P; Zouki DN; Sarris EG; Kolilekas L; Tryfonopoulos D; Papaxoinis G; Demiri S
    Case Rep Oncol; 2021; 14(2):1059-1065. PubMed ID: 34326742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcoid-like reactions in patients receiving modern melanoma treatment.
    Dimitriou F; Frauchiger AL; Urosevic-Maiwald M; Naegeli MC; Goldinger SM; Barysch M; Franzen D; Kamarachev J; Braun R; Dummer R; Mangana J
    Melanoma Res; 2018 Jun; 28(3):230-236. PubMed ID: 29485531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
    Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
    J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
    Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
    Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy-Induced Sarcoid-Like Reaction: A Shrewd Imitator.
    Yasin H; Yadala V; Khan NAJ; Graffeo V; Denning K; Lebowicz Y
    J Investig Med High Impact Case Rep; 2021; 9():23247096211009400. PubMed ID: 33847154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Therapies for Advanced Melanoma.
    Bomar L; Senithilnathan A; Ahn C
    Dermatol Clin; 2019 Oct; 37(4):409-423. PubMed ID: 31466582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
    White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
    Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
    Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
    Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.